Rawla, P. Epidemiology of prostate cancer. World J. Oncol. 10, 63–89 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hamdy, F. C. et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016).

Article  PubMed  Google Scholar 

Bill-Axelson, A. et al. Radical prostatectomy or watchful waiting in early prostate cancer. N. Engl. J. Med. 370, 932–942 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310–1319 (2009).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eggener, S. E. et al. Low-grade prostate cancer: time to stop calling it cancer. J. Clin. Oncol. 40, 3110–3114 (2022).

Article  PubMed  Google Scholar 

Etzioni, R. et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J. Natl Cancer Inst. 94, 981–990 (2002).

Article  PubMed  Google Scholar 

Gulati, R. et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control. 23, 827–835 (2012).

PubMed  PubMed Central  Google Scholar 

Schroder, F. H. et al. Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet 384, 2027–2035 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Shoag, J. E., Mittal, S. & Hu, J. C. Reevaluating PSA testing rates in the PLCO Trial. N. Engl. J. Med. 374, 1795–1796 (2016).

Article  PubMed  Google Scholar 

de, V. II, Luiting, H. B. & Roobol, M. J. Active surveillance for prostate cancer: past, current, and future trends. J. Pers. Med. 13, 629 (2023).

Article  Google Scholar 

Tsodikov, A. et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO Trials. Ann. Intern. Med. 167, 449–455 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Skouteris, V. M. et al. Transrectal ultrasound-guided versus transperineal mapping prostate biopsy: complication comparison. Rev. Urol. 20, 19–25 (2018).

PubMed  PubMed Central  Google Scholar 

Wagenlehner et al. Reducing infection rates after prostate biopsy. Nat. Rev. Urol. 11, 80–86 (2014).

Article  PubMed  Google Scholar 

Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215–224 (2003).

Article  CAS  PubMed  Google Scholar 

Chang, E. K., Gadzinski, A. J. & Nyame, Y. A. Blood and urine biomarkers in prostate cancer: are we ready for reflex testing in men with an elevated prostate-specific antigen? Asian J. Urol. 8, 343–353 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Bjurlin, M. A. et al. Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer. J. Urol. 203, 706–712 (2020).

Article  PubMed  Google Scholar 

Stabile, A. et al. Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nat. Rev. Urol. 17, 41–61 (2020).

Article  PubMed  Google Scholar 

Somford, D. M., Futterer, J. J., Hambrock, T. & Barentsz, J. O. Diffusion and perfusion MR imaging of the prostate. Magn. Reson. Imaging Clin. N. Am. 16, 685–695 (2008).

Article  PubMed  Google Scholar 

Kayhan, A., Fan, X. & Oto, A. Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer. Top. Magn. Reson. Imaging 20, 105–112 (2009).

Article  PubMed  Google Scholar 

Barentsz, J. O. et al. ESUR prostate MR guidelines 2012. Eur. Radiol. 22, 746–757 (2012).

Article  PubMed  PubMed Central  Google Scholar 

Scott, R., Misser, S. K., Cioni, D. & Neri, E. PI-RADS v2.1: what has changed and how to report. SA J. Radiol. 25, 2062 (2021).

PubMed  PubMed Central  Google Scholar 

Caglic, I., Kovac, V. & Barrett, T. Multiparametric MRI — local staging of prostate cancer and beyond. Radiol. Oncol. 53, 159–170 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Wei, J. T. et al. Early detection of prostate cancer: AUA/SUO guideline part II: considerations for a prostate biopsy. J. Urol. 210, 54–63 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Catalona, W. J. et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J. Urol. 152, 2037–2042 (1994).

Article  PubMed  Google Scholar 

Haj-Mirzaian, A. et al. Magnetic resonance imaging, clinical, and biopsy findings in suspected prostate cancer: a systematic review and meta-analysis. JAMA Netw. Open 7, e244258 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822 (2017).

Article  PubMed  Google Scholar 

Elkhoury, F. F. et al. Comparison of targeted vs systematic prostate biopsy in men who are biopsy naive: the prospective assessment of image registration in the diagnosis of prostate cancer (PAIREDCAP) study. JAMA Surg. 154, 811–818 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Buisset, J. et al. Negative prebiopsy magnetic resonance imaging and risk of significant prostate cancer: baseline and long-term followup results. J. Urol. 205, 725–731 (2021).

Article  PubMed  Google Scholar 

Moldovan, P. C. et al. What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology prostate cancer guidelines panel. Eur. Urol. 72, 250–266 (2017).

Article  PubMed  Google Scholar 

Drost, F. H. et al. Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis. Eur. Urol. 77, 78–94 (2020).

Article  PubMed  Google Scholar 

Liang, L. et al. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI. Nat. Sci. Rep. 11, 6048 (2021).

CAS  Google Scholar 

Hugosson, J. et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N. Engl. J. Med. 387, 2126–2137 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nordstrom, T. et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 22, 1240–1249 (2021).

Article  PubMed  Google Scholar 

Hao, S. et al. Cost-effectiveness of prostate cancer screening using magnetic resonance imaging or standard biopsy based on the STHLM3-MRI Study. JAMA 9, 88–94 (2022).

Google Scholar 

Hugosson, J. et al. Results after four years of screening for prostate cancer with PSA and MRI. N. Engl. J. Med. 391, 1083–1095 (2024).

Article  CAS  PubMed